Syndecan‐1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation

Aim:  To investigate the expression of syndecan‐1 in thyroid neoplasia. Syndecan‐1 is a proteoglycan regulating cell adhesion. Previous studies have demonstrated that decreased expression of syndecan‐1 is linked to malignant progression.

[1]  M. Salmivirta,et al.  Syndecan family of cell surface proteoglycans: Developmentally regulated receptors for extracellular effector molecules , 1995, Experientia.

[2]  Z. Baloch,et al.  Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. , 2002, Archives of pathology & laboratory medicine.

[3]  A. Miyauchi,et al.  Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid , 2002, British Journal of Cancer.

[4]  J. Watari,et al.  Reduced Expression of Syndecan‐1 Affects Metastatic Potential and Clinical Outcome in Patients with Colorectal Cancer , 2001, Japanese journal of cancer research : Gann.

[5]  T. Nemoto,et al.  Loss of Syndecan‐1 and Increased Expression of Heparanase in Invasive Esophageal Carcinomas , 2001, Japanese journal of cancer research : Gann.

[6]  K. Kikuchi,et al.  Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor. , 2001, Lung cancer.

[7]  C. Haglund,et al.  Epithelial and stromal syndecan‐1 expression as predictor of outcome in patients with gastric cancer , 2001, International journal of cancer.

[8]  R. Lloyd.  Distinguishing benign from malignant thyroid lesions: Galectin 3 as the latest candidate , 2001, Endocrine pathology.

[9]  S. Nordling,et al.  A prognostic value of syndecan-1 in gastric cancer. , 2000, Anticancer research.

[10]  S. Grénman,et al.  Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma. , 1999, Gynecologic oncology.

[11]  M. J. Stanley,et al.  Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. , 1999, American journal of clinical pathology.

[12]  A. Forbes,et al.  Changes in the expression of syndecan-1 in the colorectal adenoma–carcinoma sequence , 1999, Virchows Archiv.

[13]  B. Weyn,et al.  Syndecan‐1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome , 1998, The Journal of pathology.

[14]  M. Filla,et al.  The cell surface proteoglycan syndecan‐1 mediates fibroblast growth factor‐2 binding and activity , 1998, Journal of cellular physiology.

[15]  M. J. Stanley,et al.  Heparan Sulfate Proteoglycans as Adhesive and Anti-invasive Molecules SYNDECANS AND GLYPICAN HAVE DISTINCT FUNCTIONS* , 1998 .

[16]  A. Kovatich,et al.  Keratin subsets in papillary and follicular thyroid lesions , 1997, Virchows Archiv.

[17]  K. Nackaerts,et al.  Heparan sulfate proteoglycan expression in human lung‐cancer cells , 1997, International journal of cancer.

[18]  G Brabant,et al.  Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. , 1997, Cancer research.

[19]  M. Jalkanen,et al.  Syndecan-1: a new prognostic marker in laryngeal cancer. , 1997, Acta oto-laryngologica.

[20]  Y. Kohgo,et al.  Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. , 1997, International journal of cancer.

[21]  R. Gallo,et al.  Syndecans-1 and -4 are induced during wound repair of neonatal but not fetal skin. , 1996, The Journal of investigative dermatology.

[22]  M. Jalkanen,et al.  The role of syndecan-1 in malignancies. , 1996, Annals of medicine.

[23]  A. Brunet,et al.  The Mouse p44 Mitogen-activated Protein Kinase (Extracellular Signal-regulated Kinase 1) Gene , 1995, The Journal of Biological Chemistry.

[24]  W. Birchmeier,et al.  Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. , 1995, The Journal of clinical endocrinology and metabolism.

[25]  R. Sanderson,et al.  Expression of syndecan-1 inhibits cell invasion into type I collagen. , 1994, The Journal of biological chemistry.

[26]  H. Joensuu,et al.  Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. , 1994, British Journal of Cancer.

[27]  M. Jalkanen,et al.  Suppression of tumor cell growth by syndecan-1 ectodomain. , 1994, The Journal of biological chemistry.

[28]  G. Brabant,et al.  E-cadherin: a differentiation marker in thyroid malignancies. , 1993, Cancer research.

[29]  J. Woodliff,et al.  Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. , 1993, Blood.

[30]  T. Seyama,et al.  Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. , 1992, Cancer research.

[31]  M. Laato,et al.  Induced expression of syndecan in healing wounds , 1991, The Journal of cell biology.

[32]  M. Jalkanen,et al.  Cell surface proteoglycan associates with the cytoskeleton at the basolateral cell surface of mouse mammary epithelial cells , 1986, The Journal of cell biology.

[33]  A. Sakamoto,et al.  Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high‐risk group of papillary and follicular carcinomas , 1983, Cancer.

[34]  N. Samaan,et al.  Anaplastic carcinoma of the thyroid. A review of 84 cases of spindle and giant cell carcinoma of the thyroid , 1978 .